Inhibition of Ras-GTPase signaling by FPTIII ameliorates development of cardiovascular dysfunction in diabetic-hypertensive rats

Vascular Pharmacology

Volumn 49, Issue 4-6, 2008, Pages 151-157

  Yousif, Mariam H M ^a   Benter, Ibrahim F ^a   Abul, Ahmed H T ^a   Abraham, Saju ^a   Walther, Thomas ^b   Akhtar, Saghir ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carotid artery; Diabetes; FPTIII; Ischemia; Vascular dysfunction

Indexed keywords

ANGIOTENSIN II; CARBACHOL; ENDOTHELIN 1; HISTAMINE; RAS GTPASE INHIBITOR; RAS GTPASE INHIBITOR FPTIII; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE; HYPERTENSION; ISOLATED HEART; KIDNEY DYSFUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARBACHOL; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; ENDOTHELIN-1; GTP PHOSPHOHYDROLASES; HISTAMINE; HYPERTENSION; MALE; MYOCARDIAL REPERFUSION INJURY; PHOSPHONIC ACIDS; RAS PROTEINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION; STREPTOZOCIN;

EID: 55049127253     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.05.004     Document Type: Article

References (32)

1. Adachi T., Pimentel D.R., Heibeck T., Hou X., Lee Y.J., Jiang B., Ido Y., and Cohen R.A. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J. Biol. Chem. 279 (2004) 29857-29862
2. Al-Rashdan I., Canatan H., Al-Maghrebi M., Yousif M.H., Khan S.A., and Benter I.F. Cardioprotection from ischemia-reperfusion injury due to Ras-GTPase inhibition is attenuated by glibenclamide in the globally ischemic heart. Cell Biochem. Funct. 25 (2007) 455-461
3. Alvarado Y., and Giles F.J. Ras as a therapeutic target in hemotologic malignancies. Expert Opin. Emerg. Drugs 12 (2007) 271-284
4. Benter I.F., Francis I., Khan I., Cojocel C., Juggi J.S., Yousif M.H., Canatan H., Alshawaf E.H., and Akhtar S. Signal transduction involving Ras-GTPase contributes to development of hypertension and end-organ damage in spontaneously hypertensive rats-treated with L-NAME. Pharmacol. Res. 52 (2005) 401-412
5. Benter I.F., Yousif M.H., Canatan H., and Akhtar S. Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol. Res. 52 (2005) 252-257
6. Bidani A.K., and Griffin K.A. The benefits of renin-angiotensin blockade in hypertension are dependent on blood-pressure lowering. Nat. Clin. Pract. sNephrol. 2 10 (2006) 542-543 Oct
7. Bidani A.L., Picken M., Hacioglu R., Williamson G., and Griffin K.A. Spontaneously reduced BP load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance. Am. J. Physiol., Renal Physiol. 288 (2006) F353-F362
8. Burnier M., and Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J. Hypertens. 24 (2006) 11-25
9. Cardillo C., Nambi S.S., and Kilcoyne C.M. Insulin stimulates both endothelium and nitric oxide activity in the human forearm. Circulation 100 (1999) 820-825
10. Chen K., Vita J.A., Berk B.C., and Keaney Jr. J.F. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J. Biol. Chem. 276 (2001) 16045-16050
11. Cuda G., Paterno R., Ceravolo R., Candigliota M., Perrotti N., and Perticone F. Protection of human endothelial cells from oxidative stress: role of Ras-ERK1/2 signaling. Circulation 105 (2002) 968-974
12. Fang Z.Y., Prins J.B., and Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25 (2004) 543-567
13. Feener E.P., and King G.L. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail. Monit. 1 (2001) 74-82
14. Frank G.D., Eguchi S., Yamakawa T., Tanaka S., Inagami T., and Motley E.D. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology 141 (2000) 3120-3126
15. Frost J.A., Xu S., Hutchison M.R., Marcus S., and Cobb M.H. Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members. Mol. Cell. Biol. 16 (1996) 3707-3713
16. Giunti S., Barit D., and Cooper M.E. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 48 (2006) 1-8
17. Gulbins E., Coggeshall K.M., Brenner B., Schlottmann K., Linderkamp O., and Lang F. Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. J. Biol. Chem. 18 (1996) 26389-26394
18. Haidara, M.A., Mikhailidis, D.P., Rateb, M.A., Ahmed, Z.A., Yassin, H.Z., Ibrahim, I.M., Rashed, L.A., in press. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced type 1 diabetes. J. Diabetes its Complicat. Apr 22; [Electronic publication ahead of print].
19. Haworth R.S., Dashnyam S., and Avkiran M. Ras triggers acidosis-induced activation of the extracellular-signal-regulated kinase pathway in cardiac myocytes. Biochem. J. 399 (2006) 493-501
20. He Q., and LaPointe M.C. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 33 (1999) 283-289
21. Kowluru R.A., Kowluru A., Chakrabarti S., and Khan Z. Potential contributory role of H-Ras, a small G-protein, in the development of retinopathy in diabetic rats. Diabetes 53 (2004) 775-783
22. Kumagai S., Kai Y., Hanada H., Uezono K., and Sasaki H. Relationships of the systolic blood pressure response during exercise with insulin resistance, obesity, and endurance fitness in men with type 2 diabetes mellitus. Metabolism 51 (2002) 1247-1252
23. Murtuza B., Suzuki K., Bou-Gharios G., Beauchamp J.R., Smolenski R.T., Partridge T.A., and Yacoub M.H. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4216-4221
24. Muthalif M.M., Benter I.F., Khandekar Z., Gaber L., Estes A., and Malik S. Contribution of Ras-GTPase GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 35 (2000) 457-463
25. Muthalif M.M., Karzoun N.A., Gaber L., Khandekar Z., Benter I.F., Saeed A.E., Parmentier J.H., Estes A., and Malik K.U. Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36 (2000) 604-609
26. Ohtsu H., Suzuki H., Nakashima H., Dhobale S., Frank G.D., Motley E.D., and Eguchi S. Angiotensin II signal transduction through small GTP-binding proteins. Hypertension 48 (2006) 1-7
27. Pollesello P., and Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr. Opin. Crit. Care 10 (2004) 436-441
28. Rothstein E.C., Byron K.L., Reed R.E., Fliegel L., and Lucchesi P.A. H(2)O(2)-induced Ca(2+) overload in NRVM involves ERK1/2 MAP kinases: role for an NHE-1-dependent pathway. Am. J. Physiol., Heart Circ. Physiol. 283 (2002) H598-605
29. Schieffer B., Drexler H., Ling B.N., and Marrero M.B. G protein-coupled receptors control vascular smooth muscle cell proliferation via pp60c-src and p21ras. Am. J. Physiol. 272 (1997) C2019-2030
30. Tomita N., Yamasaki K., Izawa K., Kunugiza Y., Osako M.K., Ogihara T., and Morishita R. Improvement of organ damage by a non-depressor dose of imidapril in diabetic spontaneously hypertensive rats. Int. J. Mol. Med. 19 4 (2007) 571-579 Apr
31. Van Zwieten P.A., Kam K.L., Pijl A.J., Hendriks M.G., Beenen O.H., and Pfaffendorf M. Hypertensive diabetic rats in pharmacological studies. Phaf. Chem. 274 (1999) 20989-20996
32. Zwick E., Hackel P.O., Prenzel N., and Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20 10 (1999) 408-412